Skip to main content
Premium Trial:

Request an Annual Quote

AccuraGen Raises $40M in Series B Financing

NEW YORK (GenomeWeb) – Liquid biopsy startup AccuraGen said today that it has raised $40 million in a Series B financing round to support development and commercialization of its liquid biopsy technology, dubbed Firefly.

Junson Capital, Decheng Capital, Temasek investments, DT Capital, Stanford-StartX Fund, and Nan Fung Capital, along with Series A investors, participated in the round.

In addition, the company said that it had appointed Dan Zabrowski, head of sequencing and tissue diagnostics at Roche, and Junson Capital CEO Kevin Liu to its board.

AccuraGen, which has a 20-member team headquartered in Menlo Park, California and also has a 45-member clinical team in Shanghai, described its technology earlier this year at the Molecular Medicine Tri-Conference in San Francisco. AccuraGen said then that it was developing a 61-gene NGS-based test to analyzing circulating tumor DNA and conducting clinical research studies with collaborators in China.

Last year, the company raised $6.9 million in a Series A round led by Decheng Capital and Denlux Capital, along with Yifang Group Holdings Limited and WS Investment.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.